Actively Recruiting

Phase 1
Age: 18Years - 69Years
All Genders
NCT07214870

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

Led by Novo Nordisk A/S · Updated on 2026-02-11

60

Participants Needed

1

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.

CONDITIONS

Official Title

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

Who Can Participate

Age: 18Years - 69Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18-69 years at the time of signing informed consent
  • Body Mass Index (BMI) of 27.0-40.0 kg/m² at screening
  • Hepatic fat fraction of 8% or higher by MRI-PDFF within 17 days prior to dosing
  • No prior or current diagnosis of metabolic dysfunction-associated steatohepatitis (MASH)
Not Eligible

You will not qualify if you...

  • Any condition that might risk participant safety or protocol compliance
  • Previous or current use of therapies for MASH or antifibrotic treatments
  • Use of high-dose vitamin E (>800 IU/day), GLP-1 agonists, GIP/GLP-1 agonists, or pioglitazone within 6 months prior to screening
  • AST or ALT levels ≥ 1.5 times the upper limit of normal at screening
  • Total bilirubin levels > 1.5 times upper limit of normal if direct bilirubin is normal at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Altasciences Clinical Company, Inc

Montreal, Quebec, Canada, H3P 3P1

Actively Recruiting

Loading map...

Research Team

N

Novo Nordisk

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat | DecenTrialz